Piqray is a cancer medicine used to treat postmenopausal women and men with breast cancer that is locally advanced or has spread to other parts of the body. Piqray can only be used when the cancer cells have receptors for certain hormones on their surface (HR-positive) and do not have large quantities of another receptor called HER2 (HER2-negative). The cancer cells must also have been shown to have a specific mutation (change) in the gene called ‘PIK3CA’. Piqray is used with the medicine fulvestrant (hormone treatment for breast cancer) after hormone treatment used alone has failed. Piqray contains the active substance alpelisib.
Therapeutic Indication
### Therapeutic indication Piqray is indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with a PIK3CA mutation after disease progression following endocrine therapy as monotherapy (see section 5.1).
Therapeutic Area (MeSH)
ATC Code
L01XE
ATC Item
蛋白激酶抑制剂
Pharmacotherapeutic Group
Antineoplastic agents
Active Substance (Summary)
INN / Common Names
EMA Name
Piqray
Medicine Name
Piqray
Aliases
N/ANo risk management plan link.
